Search results
Results from the WOW.Com Content Network
An initial post-marketing study was updated in 2021 to verify the clinical benefits of VIGIV (CNJ-016, Vaccinia Immune Globulin Intravenous (Human), sterile solution) in the resolution of complications resulting from Orthopoxvirus vaccination in eligible patients treated with VIGIV named Clinical Outcomes of VIGIV Treatment of Smallpox ...
In Europe, the technical document is called the "summary of product characteristics" (SmPC), and the document for end-users is called the "patient information leaflet" (PIL) or "package leaflet". [3] Similar documents attached to the outside of a package are sometimes called outserts. [citation needed]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
The first report of immunizing an animal of one species (guinea pig) against the immune cells of another species (mouse lymphocytes) was by Élie Metchnikoff in 1899. He reported injecting cells recovered from mouse lymph nodes into Guinea pigs and waiting for the immunization to result in the accumulation of anti-mouse antibodies in the Guinea pig blood.
Rho(D) immune globulin is made up of antibodies to the antigen Rh o (D) present on some red blood cells. [2] It is believed to work by blocking a person's immune system from recognizing this antigen. [2] Rh o (D) immune globulin came into medical use in the 1960s, [4] following the pioneering work of John G. Gorman.
Anti-tetanus immunoglobulin, also known as tetanus immune globulin (TIG) and tetanus antitoxin, is a medication made up of antibodies against the tetanus toxin. [1] It is used to prevent tetanus in those who have a wound that is at high risk, have not been fully vaccinated with tetanus toxoid , or have HIV/AIDS .
HBIG should be given within 14 days of exposure to the hepatitis B virus. [7] The half-life of HBIG is about 3 weeks. In lieu of a booster administration of HBIG, a hepatitis B vaccination is initiated at the time of the initial HBIG administration, thus providing long term protection.
Drug-Induced Aseptic Meningitis (DIAM) is a type of aseptic meningitis related to the use of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or biologic drugs such as intravenous immunoglobulin (IVIG). [1]